AI-generated summary
The authors reviewed 27 articles on visible light therapies for vitiligo, covering helium-neon and blue LED treatments for repigmentation and Q-switched ruby and frequency-doubled Nd:YAG lasers for depigmentation. They report encouraging evidence with minimal adverse events. The authors note the evidence is limited by small studies and a lack of standardized phototherapy protocols.
- Studies included
- 27
- Who or what was studied
- Patients with vitiligo, along with preclinical and clinical studies of visible light therapy
- Wavelengths
- 380, 750, 694, 532 nm
- Limits stated in the abstract
- The evidence is limited by small studies and a lack of standardized administration of phototherapy, and larger studies are needed.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on onlinelibrary.wiley.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 380-750 nm, 694 nm, 532 nm
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Laser, Phototherapy, Red light therapy. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.